WO1998010774A2 - Utilisation de l'ozone pour le traitement de maladies des tissus de cavites corporelles et appareil prevu a cet effet - Google Patents

Utilisation de l'ozone pour le traitement de maladies des tissus de cavites corporelles et appareil prevu a cet effet Download PDF

Info

Publication number
WO1998010774A2
WO1998010774A2 PCT/IL1997/000304 IL9700304W WO9810774A2 WO 1998010774 A2 WO1998010774 A2 WO 1998010774A2 IL 9700304 W IL9700304 W IL 9700304W WO 9810774 A2 WO9810774 A2 WO 9810774A2
Authority
WO
WIPO (PCT)
Prior art keywords
gas
ozone
disease
body cavity
orifice
Prior art date
Application number
PCT/IL1997/000304
Other languages
English (en)
Other versions
WO1998010774A3 (fr
Inventor
Yefim Riskin
Original Assignee
Rid (Riskin Devices) Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL11924996A external-priority patent/IL119249A0/xx
Application filed by Rid (Riskin Devices) Ltd. filed Critical Rid (Riskin Devices) Ltd.
Priority to CA002274792A priority Critical patent/CA2274792A1/fr
Priority to AU42179/97A priority patent/AU4217997A/en
Priority to GB9913424A priority patent/GB2334676B/en
Publication of WO1998010774A2 publication Critical patent/WO1998010774A2/fr
Publication of WO1998010774A3 publication Critical patent/WO1998010774A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M13/00—Insufflators for therapeutic or disinfectant purposes, i.e. devices for blowing a gas, powder or vapour into the body
    • A61M13/003—Blowing gases other than for carrying powders, e.g. for inflating, dilating or rinsing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M13/00—Insufflators for therapeutic or disinfectant purposes, i.e. devices for blowing a gas, powder or vapour into the body
    • A61M13/003—Blowing gases other than for carrying powders, e.g. for inflating, dilating or rinsing
    • A61M13/006—Blowing gases other than for carrying powders, e.g. for inflating, dilating or rinsing with gas recirculation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/10—Preparation of respiratory gases or vapours
    • A61M16/105—Filters
    • A61M16/106—Filters in a path
    • A61M16/1065—Filters in a path in the expiratory path
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M35/00—Devices for applying media, e.g. remedies, on the human body
    • A61M35/30—Gas therapy for therapeutic treatment of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
    • A61H33/00—Bathing devices for special therapeutic or hygienic purposes
    • A61H33/14—Devices for gas baths with ozone, hydrogen, or the like
    • A61H2033/141—Devices for gas baths with ozone, hydrogen, or the like with ionised gas, e.g. ozone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/02—Gases
    • A61M2202/0216—Ozone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/75—General characteristics of the apparatus with filters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2250/00—Specially adapted for animals

Definitions

  • the invention relates to a method and apparatus for the treatment of various diseases in the cavity tissues of the human or animal body by a flow of ozone It relates particularly but not exclusively tc an apparatus for the treatment of mastitis in farm animals and especially dairy animals such as cattle, sheep, goats and camelids
  • the invention is not restricted to treating mastitis, but is relevant for treating other diseases in cavity tissues of mammals, both animal and human ⁇ REVIEW OF THE PRIOR ART
  • the introduction of therapeutic agents into the bloodstream via the oral, parenteral and rectal routes is known, and ozone has also been used for therapeutic purposes by administration by these routes.
  • US 5,133,975 discloses a method for inactivating infective agents in a patients' blood in vivo, by autochemotherapy or rectal insufflation, using as active agent a mixture of oxygen containing e.g. 30-45 ⁇ g/ml ozone.
  • Still another object of the invention is to provide the apparatus adapted for the stated purpose with means serving to prevent gas or air containing a dangerous concentration of microorganisms or other contamination from escaping into the atmosphere.
  • Yet a further object of the invention is to provide a method for the treatment of diseases of body cavity tissues.
  • the present invention provides in one aspect a method for treating a disease of a body cavity tissue in mammals, wherein a gas containing an effective amount of ozone for treating such disease is introduced inside said body cavity, provided that where the mammals are AIDS patients, then the ozone is not introduced via the rectum.
  • AIDS patients in this context is hereby defined to include also patients suffering from AIDS-related complex.
  • the invention also provides a medical apparatus for treatment of a disease of body cavity tissue by a flow of ozonized gas, which comprises means adapted for delivery of said flow of ozonized gas to body cavity tissue; means for generating said flow of ozonized gas and conduit means for transferring said ozonized gas to said delivery means; and means for providing unozonized gas and conduit means for transferring said unozonized gas to said generating means, said providing means being adapted, for example by use of an electrically driven compressor or pump, to supply gas at a pressure sufficient to drive said flow of gas after ozonization through said delivery means and into said body cavity
  • This apparatus in one embodiment is characterized additionally by at least one of the following features (a) a filtering means and means for withdrawing used ozonized gas from said body cavity and for passing said withdrawn ozonized gas through said filtering means, (b) a tubular housing having a tapering and conductive front end with the apex thereof forming an orifice and said housing having an open rear end, a coronizing electrode concentrically mounted in said housing upstream of said tapering front end and with its pointed front end extending towards said orifice, and a high voltage source having a potential of at least 2200 volts having a first terminal connected to said electrode and a second terminal connected to said conductive front end of said housing, (c) said apparatus is adapted to deliver into said cavity gas containing about 1 to about 50 p.p m ozone, (d) said apparatus is adapted for simultaneous treatment of a plurality of mammals by connecting a plurality of said delivery means to said ozone generator
  • the delivery means may be e.g.
  • a catheter which comprises an inner open-ended inlet tube for introducing said gas and an outer perforated outlet tube for removing said gas integral and coaxial therewith, the outlet tube being perforated by a plurality of openings, or a hollow needle, or a double lumen Foley catheter
  • the apparatus comprises a tubular housing of a solid material having a tapering front end of a conductive and anti-corrosive material with its apex open in the form of orifice which is sufficiently small so that said orifice constitutes said delivery means, a coronizing electrode concentrically positioned in said tube close behind the tapered front with its pointed front end extending towards said orifice, thus allowing flow of ozonized gas to be driven through said orifice thereby to contact the affected cavity tissue, and an electric high-voltage generating means attached to said apparatus characterized by a potential of at least 2200 volts, said high-voltage generating means having its high-voltage terminal connected to said electrode and its zero terminal to said tapered front end
  • This embodiment of the apparatus may be characterized additionally by at least one of the following features (I) a filtering means and means for withdrawing used ozonized gas from said body cavity and for passing said withdrawn ozonized gas through said filtering means, (n) the rear end of said tubular housing is of smaller or larger or of substantially equal diameter to that of said orifice, said rear end being optionally partly or completely open, in order to allow ingress of air as said unozonized gas, (in) said apparatus is adapted to deliver into said cavity gas containing about 1 to about 50 p p m ozone, (iv) the entire tubular housing is made of a conductive and anti-corrosive material, (v) said coronizing electrode is mounted inside said tubular housing by means of a cylindrical perforated support of a non-conductive material, permitting air to flow therethrough (vi) an motor-driven fan mounted inside said tubular housing and so disposed that it directs a flow of unozonized air in the direction of said electrode, (vn) an at least partly
  • This embodiment of the apparatus may be still further characterized by at least one of the following wherein features ( ⁇ ) feature (vu) is present and said high-voltage generating means is positioned inside a hollow portion of said handle ( ⁇ ) features (I) and (vi) are present, the filtering means being disposed upstream of said fan ( ⁇ ) feature (vi) is present, and both said electrode and said fan are mounted firmly inside tubular means of smaller diameter than and concentric with said tubular housing which has a closed rear end, thus providing an annular space between the tubular housing and the smaller diameter tubular means, whereby depending on the relative positions of said electrode and said fan, either (A) air is drawn from said orifice into the annular space and directed out via the inside of said tubular means and through said orifice, or (B) air is drawn from said orifice into the inside of said tubular means and directed out via the annular space and through said orifice, and when feature (i) is also present, then in case (A) said filtering means is disposed in said annular space and
  • the invention provides use of ozone in the manufacture of a gaseous medicament, for treating a disease of a body cavity tissue in mammals by introducing the medicament into the cavity, excluding introducing the medicament via the rectum where the mammals are AIDS patients
  • the term "AIDS patients" in this context is hereby defined to include also patients suffering from AIDS-related complex
  • the invention yet further provides use of ozone in the manufacture of a gaseous medicament, for preventing a disease of a body cavity tissue in mammals
  • Figure 1 illustrates an apparatus containing a double catheter and a conduit circuit including pumping means, an ozone generator and a filtering device
  • Figure 2 illustrates an apparatus including a supply of gas from a pressurized cylinder
  • Figure 3A is a longitudinal section of a first embodiment of the portable apparatus of the invention
  • Figure 3B is a longitudinal section of a second embodiment of the portable apparatus of the invention, characterized by ozone flow issuing from the central tube towards the diseased cavity,
  • Figure 3C is a longitudinal section of the second embodiment showing a reversed air and ozone flow, issuing from the annular channel towards the diseased cavity,
  • Figure 4 is a plan view of the soft removable sleeve to be attached to the apparatus illustrated in Figures 3B and 3C
  • Figure 5 is a section along line A-A of Figure 4.
  • the invention provides a method for treating a disease of a body cavity tissue, where a gas containing ozone may be introduced, for example, via the teat canal (e.g to treat mastitis), the rectum, the vagina, the uterus, the mouth or the larynx
  • a gas containing ozone may be introduced, for example, via the teat canal (e.g to treat mastitis), the rectum, the vagina, the uterus, the mouth or the larynx
  • Other relevant body cavities include e g the gastrointestinal tract, the peritoneal cavity, the bladder, the urethra or the urinary tract, e.g for treating cystitis.
  • the disease treated may be sinusitis; in another embodiment, in the case of non-human mammals, the disease treated may be mastitis
  • ozone may damage body tissues, or have other toxic effects, e.g. when introduced into the lungs at certain concentrations and/or for certain periods of time
  • the present invention will of course be practiced under the direction of a skilled veterinarian (in the case of non-human mammals), or under the direction of a skilled medical practitioner (in the case of humans), who will be aware of the necessity to avoid toxic effects, by limiting the concentration and/or time of administration of ozone, in accordance with the invention.
  • the gas containing ozone after use i e after having contacted the relevant body tissue, is either released into the atmosphere, or more preferably it is filtered to remove contaminants.
  • the gas is most conveniently introduced by means of a catheter inserted into said body cavity, which preferably comprises an open-ended inlet tube for introducing said gas and a perforated outlet tube for removing said gas integral therewith
  • the catheter more preferably comprises two coaxial tubes, namely an inner tube defining said inlet tube and an outer tube defining said outlet tube, the latter being perforated by a plurality of openings.
  • a catheter as just defined, also constitutes a part of the invention.
  • the invention further relates to use of ozone in the manufacture of a gaseous medicament, for treating a disease of a body cavity tissue by introducing said medicament into the cavity
  • ozone is introduced via the teat canal
  • the disease of the urinary tract is e g cystitis or pyelonephritis
  • ozone is introduced to the bladder via the urethra
  • the introduction of ozone through the teat canal serves also to remove milk residues from the udder of the cow
  • the importany body cavities in mastitis are the teat canal, teat cistern, udder cistern, molk ducts and udder aveolar cavities in increasing order of importance, and such terms as "introducing the medicament via the teat canal should be construed accordingly" herein, and similar terms, should be construed accordingly
  • the inventive apparatus includes an o
  • the catheter preferably includes an inner supply tube of about 1 mm diameter (through which the ozonized gas is normally introduced) and this is surrounded by a perforated tube (normally used for return of the gas) of about 3 mm diameter
  • the gas-ozone mixture may be injected through the outer tube and returned via through the inner tube, although the former method is more efficient
  • the catheter may consist of two parallel tubes, a small diameter tube for injection and a tube of somewhat larger diameter for returning the gas either to the filter or into the atmosphere.
  • the catheter has to be thoroughly disinfected after each treatment, or alternatively a new sterile catheter may be used in each case
  • the compressor or pump may be omitted completely, and in this case the gas may be supplied from a gas cylinder through a pressure regulator and pressure gauge
  • a catheter composed of an inner tube 10 is connected to a flexible supply conduit 3, with an open end 11 , through which the gas-ozone mixture enters the udder or other body cavity.
  • Inner tube 10 is surrounded by a coaxial outer tube 12 of a diameter permitting ready insertion into the body cavity, tube 12 being perforated by a plurality of oblong openings 13 for the return flow of the gas mixture from the udder or other body cavity
  • Tube 12 is connected to a flexible return conduit 23, leading to a filtering device 4, which contains a special replaceable filter 5 designed to absorb any residual ozone (which is corrosive); the exhaust gas may be passed additionally through a conventional liquid trap (not shown) to remove any microorganisms which may be present, before exiting to the atmosphere.
  • Air is drawn into the by compressor or pump 6, which may contain an upstream filter (not shown) to remove undesired particulate matter (such as dust and larger particles), and which is connected to an electrical supply via cable 16.
  • a conduit 43 connects the compressor to an ozone generator 7, which generates ozone by means of coronizing electrode 17, connected to a transformer-rectifier unit 18, which is in turn connected to an electrical supply by means of cable 19.
  • the ozone-enriched gas reaches the catheter through flexible conduit 3.
  • the ozone generator includes a tubular housing having a tapering and conductive front end with the apex thereof forming an orifice and said housing having an open rear end, a coronizing electrode concentrically mounted in said housing upstream of said tapering front end and with its pointed front end extending towards said orifice, and a high voltage source having a potential of at least 2200 volts having a first terminal connected to said electrode and a second terminal connected to said conductive front end of said housing
  • a coronizing electrode concentrically mounted in said housing upstream of said tapering front end and with its pointed front end extending towards said orifice
  • a high voltage source having a potential of at least 2200 volts having a first terminal connected to said electrode and a second terminal connected to said conductive front end of said housing
  • the apparatus of the invention may alternatively be constituted by a hand-held and portable device adapted to generate and to direct air containing ozone towards the opening of a large external body cavity, in particular the mouth, thereby to facilitate treatment of diseases, where the site of the disease is accessible via this body cavity
  • This device will be referred to in subsequent description herein as the "portable apparatus (of the invention)"
  • a first embodiment of the portable apparatus of the invention includes a tube of a solid material having a tapering front end of a conductive and anti- corrosive material with its apex open in the form of a small-diameter orifice, and having a rear end partly or completely open, but of larger cross section than that of the orifice
  • An electrode is concentrically positioned close behind the tapered front with its pointed front end extending towards the orifice
  • An electric high-voltage generator, e g a transformer is attached to the apparatus and is characterized by a potential of at least 2,200 volts it has its high-voltage terminal connected to the electrode and its earth terminal to the tapered front end which thus forms the second electrode
  • the generator is supplied energy from the domestic supply by means of a flexible cable
  • the motion of the ions creates a certain pressure causing the air and the ozone molecules to emerge out of the orifice which may have a diameter of between 2 to 10 mm
  • the tube is held with the orifice suitably directed to the body cavity (e g the mouth) of the patient for a predesignated period of time, the air and the ozone particles emerge out of the orifice and impinge on the diseased locus so as to effect, improve and accelerate the curative process
  • the portable apparatus is preferably provided with a hollow handle which carries the generator inside and which enables the operator to position the apparatus in a correct position for treating the ailment
  • a hollow handle which carries the generator inside and which enables the operator to position the apparatus in a correct position for treating the ailment
  • the size of the orifice can be made of a suitable size, smaller or larger, depending on its particular application, it may be desirable to increase the voltage potential, where the orifice is relatively large
  • the air flow is recirculated by a motor-driven fan positioned therein
  • the tube containing the electrode has two open ends and is enclosed in a housing in the form of a larger tube having its rear end closed, whereby an annular channel is formed between the two tubes
  • An axial fan mounted inside the inner tube sucks in air from the front end of the channel and blows it across the corona discharge generated by the electrode in the direction of the affected body cavity
  • An annular filter positioned in the annular channel serves to filter the air returned from the body cavity and to permit clean air to reach the fan and the electrode
  • the portable apparatus is provided with a handle and a high-voltage generator enclosed in the handle
  • the inner tube is either made completely of a conductive and non-corrosive material or is composed of two parts, a conductive portion surrounding the corona and the remaining portion of any other material
  • the air-flow is reversed, i e air is sucked in through the inner tube, filtered by a circular filter positioned in this tube before reaching the electrode, and is ejected through the annular channel to the front, and thence in the desired direction
  • a soft resilient sleeve may be mounted on the front of the apparatus which is disposed of after each session of treatment in order to prevent infectious transfer from one patient to another
  • High-voltage charge on the electrode is generated by a transformer provided with rectifier and attenuating means to effect one side, connected to the electrode, to produce high voltage connected to the electrode and the other, zero, side, connected to the inner tube and to earth
  • Figure 3A shows the principle of the working of a portable ozone treating apparatus It includes a tubular oblong housing 101 of a conductive material which is open at its rear end 102 defining an air inlet, and has a tapering front end 103 closing the housing, except for a small orifice defining the air-ozone outlet 104 It further includes a centrally positioned coronizing electrode 106 which is provided with a pointed front end pointing towards the orifice in concentric alignment therewith and being held in position by an annular perforated support 105 of an inert material It is important that the housing is anti-corrosive, at least in the tapering portion which is exposed to the oxidizing action of the ozone
  • a handle 110 is attached to the outside of the housing, facilitating operation of the apparatus and contains a high-voltage generator or transformer 107 in its hollow interior
  • the high-potential terminal of the transformer is connected to electrode 106 by conductor 109, and its low- potential terminal to the housing 101 at point 109
  • the high voltage - at least 2200 volts - generates, in a known manner, a corona discharge 111 towards the tape ⁇ ng front end of the housing which splits and combines a small portion of the oxygen molecules in the surrounding air, whereby atoms O combine with O 2 to form ozone molecules O 3
  • the corona exerts a very small pressure towards the orifice thereby driving the air and ozone out of the housing and directed towards or into the patient's body cavity
  • the apparatus illustrated in Figure 3B is composed of tubular housing 120 of a solid material which has an open front end and a rear end closed by a hemispherical cover 122 and of an inner concentrically positioned tube 121 of a conductive and anti-corrosive material, having two open ends Both tubes are in concentric alignment, forming an annular channel 123 therebetween which contains a highly absorbing annular filter 124 in its front
  • the filter and three to four arms 135 extending inwardly from the housing hold the inner tube in its position
  • a coronizing sharp-pointed electrode 125 is positioned in the center of the inner tube by means of a circular perforated support 126 with its sharp point extending towards the open front of the apparatus It is connected to the high- potential terminal of a transformer or other high-voltage generator 127 which is mounted inside a handle 130, the low potential terminal being connected to the conductive tube 121
  • An axial blower 128 is mounted inside the inner tube 121 , configured to blow clean air towards the electrode and out through the open front, its electric motor is supplied domestic current through wiring 129 extending through the housing 120 and the handle 130
  • a frusto-conical sleeve 131 of a soft and resilient material - as shown in Figures 4 and 5 - is removably attached to the front of the housing and is disposed of after each treatment
  • the electrode being supplied with high voltage creates a corona discharge towards the inner, earthed tube generating a certain small amount of ozone which is driven towards the patient's body cavity opening by the force of the axial fan
  • the used air is returned into the apparatus by suction action of the axial fan, it passes the filter 124 where all remaining ozone molecules are absorbed and is recirculated through annular channel 123 into the inner tube as shown by arrows, thereby preventing ozone from being dispersed into the surrounding space
  • FIG 3C shows an apparatus similar to that shown in Figure 3B, and the same numerals are employed in both figures to denote identical components, even if they are in a different position in both cases
  • the housing 120, the handle 130 and the inner tube 121 are completely identical with those illustrated in Figure 3B, the difference lying in the reversed air flow Air is sucked in by action of fan 128 and is conveyed through a cylindrical filter 144 - inside tube 121 - to electrode 125 which points towards the rear of the housing
  • the ozone-containing air now passes through the annular channel 123 and the soft sleeve 131 into the patient's body cavity
  • the air from the patient's body cavity is returned to the electrode after having passed the highly efficient filter 144 mounted in the front end of the inner tube, the filter preferably containing activated carbon for absorbing the remaining ozone molecules
  • the inner tube has been mentioned as being preferably of a conductive and anti-corrosive material It should however be mentioned that only that portion of the tube which is in contact with the corona discharge may be made of this material, while the remaining portion may be of any suitable solid material, whether conductive or not
  • a particular advantage of the invention lies in the fact that the milk obtained will be suitable for consumption immediately after treatment has been concluded, whereas when using antibiotics, consumption must be delayed for several days.
  • the present is particularly directed to the treatment of mastitis, by introducing a gas containing ozone through the teat canal, it will be understood that it is likewise suitable for ozone treatment of various diseases in cavity tissues of the human or animal body, such as the rectum, the vagina (e.g. vaginitis), the uterus, the mouth or the larynx.
  • Uterine diseases e.g., metritis and endometritis, frequently occur especially in a veterinary context either spontaneously or in cases of retained placenta or postpartum complications; for treatment of such diseases ozone would be introduced through the cervical opening.
  • the present invention is also of relevance to treatment of diseases in other body cavities such as the gastrointestinal tract, the peritoneal cavity, the bladder, the urethra or the urinary tract, e.g. for treating cystitis.
  • the present invention also contemplates treatment of gastroenteritis, particularly in the veterinary field, e.g. in relation to neonatal animals.
  • gastroenteritis may be associated with various microorganisms such as bacteria, fungi, viruses and protozoa.
  • Conditions of the bladder/urethra/urinary tract which are contemplated as amenable to treatment in accordance with the invention include acute or chronic bladder inflammation due to various microorganisms, cystitis, pyelonephritis and ureteritis.
  • a flow of gas of about 1 to 5 liters (e.g. 3-4) per minute, containing from 1 to 50 (e.g. 20-30) p.p.m. of ozone, for intermittent periods of 1 to 20 (e.g. about 10) minutes, using the catheter described herein, has given excellent results and can be effective in curing the disease within a few days, although one or two days may be sufficient. In most cases.
  • the gas to be ozonized will usually be clean (uncontaminated) air, but in the alternative it is also possible to use bottled gas such as oxygen, which has been ozonized. See also Examples 5 and 6m below.
  • EXAMPLE 2 For the treatment of gastroenteritis, use may be made of the catheter described herein, for introducing ozonized air into the rectum, via the anus, the parameters otherwise being as described in Example 1. Alternatively, the ozonized air may be introduced through a needle inserted through the linea alba into the peritoneal cavity. In either case, the pressure must be carefully controlled.
  • EXAMPLE 3 For the treatment of cystitis, use may be made of a double lumen Foley catheter, for introducing ozonized air into the bladder, via the urethra, the parameters otherwise being as described in Example 1.
  • EXAMPLE 4 For the treatment of metritis, endometritis or pyometra, use may be made of a double lumen Foley catheter, for introducing ozonized air into the uterus, via the cervical canal, the parameters otherwise being as described in Example 1.
  • EXAMPLE 5 In this Example, the efficacy of intramammarily administered ozone gas was evaluated in experimental Escherichia coli mastitis in dairy cows.
  • the milking equipment was computer controlled with an electronic auto-identification, pedometer and milk conductivity monitoring system (Afimilk®, computerized dairy management systems, S.A.E. Afikim, Kibbutz Afikim 15148, Israel). All cows were also identified by freeze brand marks. Mammary glands were eligible for experimental infection only if the foremilk SCC was less than 400,000/ml of milk and if major udder pathogens were not isolated from milk samples collected daily for three consecutive days prior to the day of infection. (Cow 852 was salvage slaughtered on day 12 after infection due to metatarsal fracture.)
  • the actual inoculum concentration was determined before and after udder inoculation by pour plating in eosin methylene blue (EMB) agar, the counts ranged 400 to 750 cfu/ml. Infections were made immediately after the morning milking. Teats were dipped in iodophor teat dip, scrubbed with 70% ethanol and allowed to dry. Using a sterile, disposable, 2.5 inch blunt cannula, 1.0 ml of the bacterial suspension was infused via the teat canal. Seventeen cows were infused into diagonal front and hind quarters, 3 into front quarters, 2 into left quarters and 1 into hind quarters (see Appendix 4 for individual cow quarter inoculation site). Treatment
  • Cows were randomly allocated into 2 treatment groups, 12 cows per group (one cow developed clinical mastitis before experimental inoculation and was withdrawn) Eleven cows received a priming dose of 20 g of sulfadiazine Na and 4 g of t ⁇ methoprim (Diazip ⁇ m Forte ® , Vitamed Ltd , Batyam, Israel) intramuscularly and additional intramuscular treatment of 10 g of sulfadiazine Na and 2 g of t ⁇ methop ⁇ m after 24 hours Twelve cows were treated intramamma ⁇ ly, 6 times at 8 hours intervals, with a gaseous mixture (generated as described herein) containing air and ozone applied to the inoculated quarters only P ⁇ or to treatment it was ascertained that the ozonized air did not contain any noxious components such as nitrogen oxides
  • the gaseous mixture contained 40 ppm ozone and was applied at a pressure of 1 atm and a flow rate of 150 L per hour for 5 minutes
  • Jugular blood samples were collected in plain and EDTA vacuum blood tubes once daily for two consecutive days before infection and 4, 12, 16 and 24 hours after udder inoculation and once daily for the following 7 days
  • Whole blood was analyzed for complete white blood cell counts (WBC), and hematocrit (Ht)
  • Serum samples were analyzed for total calcium, total serum protein (TSP), aspartate serum transammase (AST), urea, creatinine, inorganic phosphorus and sodium
  • TSP total serum protein
  • AST aspartate serum transammase
  • urea creatinine
  • inorganic phosphorus inorganic phosphorus and sodium
  • the bacteriological infection success rate was assessed by duplicate culture samples taken 6 hours post inoculation and at pretreatment time.
  • the bacteriological cure rate was assessed by duplicate culture samples taken at days 7 and 14 post treatment All samples taken from successfully infected quarters at a specific time should have been negative for E coli to achieve bacteriological cure E coli were cultured at 6 hours after inoculation and/or before treatment from 100% (24/24) and 95 5% (21/22) of inoculated quarters of ozone and STM treatment group cows respectively
  • the cure rate for the ozone treatment group was 50% (12/24) on day 7 post infection and 83 3 8% (20/24) on day 14 post infection Twelve quarters (50%) of the successfully infected quarters were culture negative for E coli on both post treatment samples
  • the cure rate for the STM treatment group was 42 9% (9/21 ) on day 7 and 85 7% (18/21) on day 14 post infection Eight quarters (38 1%) of the successfully infected quarters were culture negative for E coli on both post
  • the bacteriological cure rates were higher for the ozone treatment group in comparison to the sulfadiazine trimethoprim treatment group, however, these differences were not statistically significant.
  • Cows were randomly allocated into 2 treatment groups, 6 cows per group (one cow developed clinical mastitis before experimental inoculation and was withdrawn)
  • Five cows received a priming dose of 20 g of sulfadiazine Na and 4 g of trimethoprim (Diazip ⁇ m Forte ® , Vitamed Ltd , Batyam, Israel) intramuscularly and additional intramuscular treatment of 10 g of sulfadiazine Na and 2 g of trimethoprim after 24 hours
  • Six cows were treated intramammarily, 6 times at 8 hours intervals, with a gaseous mixture generated as described herein) containing air and ozone applied to the inoculated quarters only Prior to treatment it was ascertained that the ozonized air did not contain any noxious components such as nitrogen oxides
  • the gaseous mixture contained 7 ppm ozone (and was applied at a pressure of 2 atm and a flow rate of 300 L per hour for 10 minutes
  • Duplicate quarter milk samples were aseptically collected from all quarters of each cow for bacteriological culture and SCC at 6 hours after infection, immediately pre-treatment time and 7 and 14 days post treatment.
  • Bacteriological examination for udder pathogens was performed as previously described, using standard methods Milk SCC were measured with Fossomatic instrument (Foss Electric, Hillend, Denmark) Concurrently with the clinical examination, the California Mastitis Test (CMT) was performed and recorded using 0, 1 , 2, 3, 4 scale
  • Jugular blood samples were collected in plain and EDTA vacuum blood tubes once daily for two consecutive days before infection and 4, 12, 16 and 24 hours after udder inoculation and once daily for the following 7 days
  • Whole blood was analyzed for complete white blood cell counts (WBC), and hematoc ⁇ t (Ht) Serum samples were analyzed for total calcium, total serum protein (TSP), aspartate serum transaminase (AST), urea, creatinine, inorganic phosphorus and sodium
  • WBC white blood cell counts
  • Ht hematoc ⁇ t Serum samples were analyzed for total calcium, total serum protein (TSP), aspartate serum transaminase (AST), urea, creatinine, inorganic phosphorus and sodium
  • TSP total serum protein
  • AST aspartate serum transaminase
  • urea creatinine
  • creatinine inorganic phosphorus and sodium
  • the bacteriological infection success rate was assessed by duplicate culture samples taken 6 hours post inoculation and at pretreatment time.
  • the bacteriological cure rate was assessed by duplicate culture samples taken at days 7 and 14 post treatment. All samples taken from successfully infected quarters at a specific time should have been negative for E. coli to achieve bacteriological cure.
  • E.coli were cultured at 6 hours after inoculation and/or before treatment from 80% (8/10) and 100% (10/10) of inoculated quarters of ozone and STM treatment group cows respectively.
  • the cure rate for the ozone treatment group was 62.5% (5/8) on day 7 post infection and 87.5% (7/8) on day 14 post infection.
  • Four quarters (50%) of the successfully infected quarters were culture negative for E. coli on both post treatment samples.
  • the cure rate for the STM treatment group was 100% (10/10) on day 7 and 100% (10/10) on day 14 post infection (see Table 2).
  • Table 2 Bacteriological infection rates and cure rates of infused quarters in the ozone and sulfatrimethoprim (STM) treatment groups.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)

Abstract

L'invention concerne l'utilisation d'ozone dans la fabrication d'un médicament gazeux pour le traitement d'une maladie d'une cavité corporelle chez les mammifères par l'introduction du médicament dans ladite cavité. Elle porte aussi sur un appareil comprenant un générateur d'ozone et des moyens d'alimentation en gaz ozoné depuis ce dernier, à une pression suffisante pour acheminer un flux dudit gaz dans un moyen de distribution et dans la cavité corporelle. Les maladies pouvant être traitées de cette manière sont par exemple la mammite chez les vaches et la cystite.
PCT/IL1997/000304 1996-09-12 1997-09-11 Utilisation de l'ozone pour le traitement de maladies des tissus de cavites corporelles et appareil prevu a cet effet WO1998010774A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002274792A CA2274792A1 (fr) 1996-09-12 1997-09-11 Utilisation de l'ozone pour le traitement de maladies des tissus de cavites corporelles et appareil prevu a cet effet
AU42179/97A AU4217997A (en) 1996-09-12 1997-09-11 Use of ozone for treating diseases of body cavity tissues and apparatus there for
GB9913424A GB2334676B (en) 1996-09-12 1997-09-11 Use of ozone for treating diseases of body cavity tissues and apparatus therefor

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IL11924996A IL119249A0 (en) 1996-09-12 1996-09-12 Therapeutic ozone treating apparatus
IL119249 1996-09-12
IL119835 1996-12-15
IL11983596A IL119835A0 (en) 1996-09-12 1996-12-15 Medical apparatus and method for treating diseases in humans and animals

Publications (2)

Publication Number Publication Date
WO1998010774A2 true WO1998010774A2 (fr) 1998-03-19
WO1998010774A3 WO1998010774A3 (fr) 1998-07-30

Family

ID=26323303

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL1997/000304 WO1998010774A2 (fr) 1996-09-12 1997-09-11 Utilisation de l'ozone pour le traitement de maladies des tissus de cavites corporelles et appareil prevu a cet effet

Country Status (6)

Country Link
AR (1) AR008178A1 (fr)
AU (1) AU4217997A (fr)
CA (1) CA2274792A1 (fr)
GB (1) GB2334676B (fr)
IL (1) IL119835A0 (fr)
WO (1) WO1998010774A2 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG128439A1 (en) * 2002-04-12 2007-01-30 Shenzhen Mermaid Industry Dev Method and apparatus for cleansing the lower intestinal tract
WO2008028723A1 (fr) * 2006-07-24 2008-03-13 Wolfgang Herrmann Systeme de dosage d'ozone ou d'un melange ozone/oxygene
WO2008085364A1 (fr) * 2006-12-26 2008-07-17 Ceramatec, Inc. Appareil et procédé pour traiter et distribuer une matière dans un tissu
EP2088121A1 (fr) 2008-02-08 2009-08-12 "Oxy 3" Egger KEG Unité transportable pour la production d'ozone
US7615030B2 (en) 2003-10-06 2009-11-10 Active O, Llc Apparatus and method for administering a therapeutic agent into tissue
WO2009117425A3 (fr) * 2008-03-20 2009-12-23 Ceramatec, Inc. Sonde électrochimique et procédé pour le traitement in situ d'un tissu
EP2532341A1 (fr) * 2011-06-07 2012-12-12 Burghardt Krebber Kit de parties pour le traitement des maladies infectieuses
WO2014085945A1 (fr) * 2012-12-07 2014-06-12 Medela Holding Ag Dispositif d'aspiration avec conduite de drainage balayable à l'air
US8777889B2 (en) 2004-06-15 2014-07-15 Ceramatec, Inc. Apparatus and method for administering a therapeutic agent into tissue
CN105395352A (zh) * 2015-12-06 2016-03-16 陈建梅 妇科炎症治疗修复装置

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001280404A1 (en) * 2000-08-16 2002-02-25 Violetta Silfver Method and device for treating inter alia the cervix

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2943310A1 (de) * 1979-10-26 1981-05-14 Paetz, Drmed., Günther, 3170 Gifhorn Geraet zur leitung von therapeutisch wirksamen strahlungen einer bestimmten wellenlaenge - ueberwiegend uv-c-strahlung sowie ionisierungsfaehiger gase und gasgemische - im blut - und lymphgefaesse, koerpereigenen wie auch koerperfremden fluessigkeiten, substanzen, organen und in natuerlichen wie kuenstlich geschaffenen hohlraeumen bei menschen und tieren sowie isolierten organen
DE3119581A1 (de) * 1981-05-16 1982-12-09 Horst Dr.Med. 6700 Ludwigshafen Kief "infusion fuer gasfoermige medien"
DE3404029A1 (de) * 1984-02-06 1985-08-08 Cuto, Veronika, 1000 Berlin Tragbares inhalationsgeraet
EP0339924A2 (fr) * 1988-04-29 1989-11-02 Medizone International, Inc. Appareil pour la génération et l'administration contrôlée d'ozone
EP0555582A2 (fr) * 1992-02-13 1993-08-18 Med-Pro Design, Inc. Cathéter coaxial
EP0653219A1 (fr) * 1993-11-16 1995-05-17 Tradotec S.A. Procédé pour produire un mélange gazeux hypoxique

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2943310A1 (de) * 1979-10-26 1981-05-14 Paetz, Drmed., Günther, 3170 Gifhorn Geraet zur leitung von therapeutisch wirksamen strahlungen einer bestimmten wellenlaenge - ueberwiegend uv-c-strahlung sowie ionisierungsfaehiger gase und gasgemische - im blut - und lymphgefaesse, koerpereigenen wie auch koerperfremden fluessigkeiten, substanzen, organen und in natuerlichen wie kuenstlich geschaffenen hohlraeumen bei menschen und tieren sowie isolierten organen
DE3119581A1 (de) * 1981-05-16 1982-12-09 Horst Dr.Med. 6700 Ludwigshafen Kief "infusion fuer gasfoermige medien"
DE3404029A1 (de) * 1984-02-06 1985-08-08 Cuto, Veronika, 1000 Berlin Tragbares inhalationsgeraet
EP0339924A2 (fr) * 1988-04-29 1989-11-02 Medizone International, Inc. Appareil pour la génération et l'administration contrôlée d'ozone
EP0555582A2 (fr) * 1992-02-13 1993-08-18 Med-Pro Design, Inc. Cathéter coaxial
EP0653219A1 (fr) * 1993-11-16 1995-05-17 Tradotec S.A. Procédé pour produire un mélange gazeux hypoxique

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
A.A. PRIYMAK ET AL.: "An Ozone-Oxygen Mixture of Myobacterium Tuberculosis and Opportunistic Microorganisms" PROBLEMY TUBERKULEZA, no. 4, 1991, pages 7-10, XP002053175 *

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG128439A1 (en) * 2002-04-12 2007-01-30 Shenzhen Mermaid Industry Dev Method and apparatus for cleansing the lower intestinal tract
US7615030B2 (en) 2003-10-06 2009-11-10 Active O, Llc Apparatus and method for administering a therapeutic agent into tissue
US8162873B2 (en) 2003-10-06 2012-04-24 Ceramatec, Inc. Apparatus for administering a therapeutic agent into tissue
US8066695B2 (en) 2003-10-06 2011-11-29 Ceramatec, Inc. Implantable apparatus for administering a therapeutic agent into tissue
US8066659B2 (en) 2004-06-15 2011-11-29 Ceramatec, Inc. Apparatus and method for treating and dispensing a material into tissue
US8986520B2 (en) 2004-06-15 2015-03-24 Ceramatec, Inc. Apparatus administering a therapeutic agent into tissue
US8777889B2 (en) 2004-06-15 2014-07-15 Ceramatec, Inc. Apparatus and method for administering a therapeutic agent into tissue
US8591472B2 (en) 2004-06-15 2013-11-26 Ceramatec, Inc. Apparatus for administering a therapeutic agent into tissue using a needle as the material treatment module
US8353906B2 (en) 2005-08-01 2013-01-15 Ceramatec, Inc. Electrochemical probe and method for in situ treatment of a tissue
WO2008028723A1 (fr) * 2006-07-24 2008-03-13 Wolfgang Herrmann Systeme de dosage d'ozone ou d'un melange ozone/oxygene
WO2008085364A1 (fr) * 2006-12-26 2008-07-17 Ceramatec, Inc. Appareil et procédé pour traiter et distribuer une matière dans un tissu
JP2010514500A (ja) * 2006-12-26 2010-05-06 セラマテック・インク 生体組織への材料の処理及び分配装置および方法
EP2088121A1 (fr) 2008-02-08 2009-08-12 "Oxy 3" Egger KEG Unité transportable pour la production d'ozone
WO2009117425A3 (fr) * 2008-03-20 2009-12-23 Ceramatec, Inc. Sonde électrochimique et procédé pour le traitement in situ d'un tissu
EP2532341A1 (fr) * 2011-06-07 2012-12-12 Burghardt Krebber Kit de parties pour le traitement des maladies infectieuses
WO2014085945A1 (fr) * 2012-12-07 2014-06-12 Medela Holding Ag Dispositif d'aspiration avec conduite de drainage balayable à l'air
CH707315A1 (de) * 2012-12-07 2014-06-13 Medela Holding Ag Absaugvorrichtung mit spülbarer Drainageleitung.
US9486561B2 (en) 2012-12-07 2016-11-08 Medela Holding Ag Suction apparatus with a flushable drainage line
CN105395352A (zh) * 2015-12-06 2016-03-16 陈建梅 妇科炎症治疗修复装置

Also Published As

Publication number Publication date
AR008178A1 (es) 1999-12-09
AU4217997A (en) 1998-04-02
CA2274792A1 (fr) 1998-03-19
GB9913424D0 (en) 1999-08-11
WO1998010774A3 (fr) 1998-07-30
GB2334676A (en) 1999-09-01
IL119835A0 (en) 1997-03-18
GB2334676B (en) 2001-04-04

Similar Documents

Publication Publication Date Title
JP4658054B2 (ja) 表面を殺菌する装置とその方法
OGATA et al. Intramammary application of ozone therapy to acute clinical mastitis in dairy cows
US20050256553A1 (en) Method and apparatus for the treatment of respiratory and other infections using ultraviolet germicidal irradiation
WO1998010774A2 (fr) Utilisation de l'ozone pour le traitement de maladies des tissus de cavites corporelles et appareil prevu a cet effet
NL1005846C2 (nl) Werkwijze voor het behandelen van huisdieren, zoals koeien, tegen mastitis, en inrichting voor het in uiers injecteren van ozon.
ROSS et al. Closed suction drainage in the treatment of infectious arthritis of the equine tarsocrural joint
Khushvakova et al. Local complex treatment experience for patients with chronic purulent otitis media
Liu et al. A therapeutic effect of ozonated oil on bovine mastitis
WO1998010825A1 (fr) Utilisation de l'ozone pour la fabrication de medicaments gazeux
JP3022341B2 (ja) 牛の乳房用オゾン注入装置
CN104971424A (zh) 一种耳部疾病臭氧治疗系统
DE69330817T2 (de) Heilvorrichtung
CN204723590U (zh) 一种耳部疾病臭氧治疗系统
CN215780665U (zh) 一种儿科医用紧急雾化器
KR100239129B1 (ko) 소 등의 가축의 유방용 오존주입장치
Agrawal et al. Pharmacokinetics of amikacin in goats after single intramuscular administration
CN208407946U (zh) 高压氧排氧管路消毒装置
RU2181595C2 (ru) Способ лечения острого эндометрита у коров
RU2180221C2 (ru) Способ лечения субклинического мастита у коров
JPH09289995A (ja) 牛の乳房用オゾン注入装置
RU2142805C1 (ru) Способ повышения резистентности организма новорожденных поросят
Babur Usage areas of ozone in animal health as an alternative treatment method: Usage ozone in animal health
RU2239445C1 (ru) Способ лечения субклинического мастита у лактирующих коров
RU2165745C2 (ru) Способ лечения субклинического мастита у коров
SU876138A1 (ru) Способ лечени полых органов

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WPC Withdrawal of priority claims after completion of the technical preparations for international publication
ENP Entry into the national phase

Ref document number: 2274792

Country of ref document: CA

Ref country code: GB

Ref document number: 9913424

Kind code of ref document: A

Format of ref document f/p: F

Ref country code: CA

Ref document number: 2274792

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09330487

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase